Happy to share our latest work in Merkel cell carcinoma immunotherapy published today in Cancer Discovery Cancer Discovery from the Choi Lab Jaehyuk Choi in collaboration with the Tsai lab Kenneth Y. Tsai. aacrjournals.org/cancerdiscover…

Delighted to see the work from my collaboration with Jaehyuk Choi out today in Cancer Discovery . Don't miss the great tweetorials from Jaehyuk Choi and Zachary Reinstein. Calling out Oscar Ospina Carlos Moran-Segura and members of my lab, Cutaneous Oncology and ... (1/2)

Moffitt Cancer Center Now online in Cancer Discovery : Pre-Existing Skin-Resident CD8 and γδ T Cell Circuits Mediate Immune Response in #MerkelCellCarcinoma & Predict Immunotherapy Efficacy Zachary Reinstein Jaehyuk Choi & colleagues doi.org/10.1158/2159-8…… Northwestern Feinberg School of Medicine Lurie Cancer Center Moffitt Cancer Center

The Agenus paper on Botensilimab with preclinical data, plus early phase trial with monotherapy & dual combo is on Cancer Discovery: Botensilimab, an Fc-enhanced anti-CTLA-4 antibody, is effective against tumors poorly responsive to conventional immunotherapy aacrjournals.org/cancerdiscover…

Our discovery of potent WRN inhibitors is out in print today in Cancer Discovery. Originally published online in April in advance of AACR annual meeting, and closely followed by two reports of additional inhibitors. Great to see WRN inhibitors moving towards the clinic.

Very stimulating study. Fully aligned with our findings of anti-CTLA4 mode of action aacrjournals.org/cancerdiscover…

It is great to see our work published in this issue of Cancer Discovery and commented on by Zev Wainberg in the Spotlight section, discussing the clinical potential of developing WRN inhibitors! aacrjournals.org/cancerdiscover…

We’re pleased to share our latest study in Cancer Discovery on botensilimab’s mechanism of action and its potential in addressing treatment-resistant cancers. Read more: bit.ly/4dfbPvA #CancerResearch #Immunotherapy #CancerTreatment

Great to be here at the Johns Hopkins Medicine Dept of Neurosurgery Hunterian Celebration, reunite with so many fantastic friends, and hear great research!

On my way to hear the latest exciting advances in #cancer treatment and research at #ESMO2024: happy to talk about publishing in ⁦Cancer Discovery⁩ !

The ⁦AACR⁩ team is here at #ESMO24: come by and become an AACR member for free 😊

Fantastic #ESMO24 talk from Alexander Drilon MD Memorial Sloan Kettering Cancer Center about the ph1/2 efficacy of NVL-655, a brain penetrant ALK inhibitor (single and compound ALK resistance mutations): check out the related Cancer Discovery paper (online yesterday!) 👉🏻aacrjournals.org/cancerdiscover…

💊 Phase 1/2 ALKOVE-1 study of NVL-655 in ALK+ solid tumors presented by Alexander Drilon MD 🌟 Remarkable ORR across different settings with many durable responses and 🧠 activity, and TRK-sparing tox confirming the drug design rational. #ESMO24 #LCSM

#ESMO24 Dr. Alexander Drilon MD presents ALKOVE-1: NVL-655 in #ALK NSCLC. NVL-655 is a rationally designed ALK inhibitor that spares TRK (which should improve tolerability). In escalation, MTD not reached. Here, update on efficacy and safety. Excellent team w/ Drs. JessicaJLinMD

Dr. Alexander Drilon MD presents ph 1/2 ALKOVE-1 study of NVL-655 - a novel next-generation ALK-targeted TKI w/ CNS penetrative at #ESMO24.

Fantastic proffered papers in NSCLC session this morning at #ESMO24. For me the highlight was NVL-655. I think ALK patients need compassionate access to this while trials recruit. So many pts won’t be eligible or live too far away from a recruiting centre.

🌟And here with the efficacy and safety data of #NVL655, ALK-selective, TRK-sparing and brain-penetrant 4G ALK TKI, from ALKOVE-1, presented today #ESMO24 by Alexander Drilon MD ✅ ORR 38% in heavily pretreated pts overall (1-5 prior ALK TKIs) ✅ ORR 35% in pts post-lorlatinib (in which

So great to meet up with Daniel Gerlach at #ESMO24! And be sure to read about the irreversible HER2 TKI he and colleagues very recently published in Cancer Discovery 👉🏻 aacrjournals.org/cancerdiscover…

ICYMI in Cancer Discovery: D3S-001, a #KRAS G12C Inhibitor with Rapid Target Engagement Kinetics, Overcomes Nucleotide Cycling and Demonstrates Robust Preclinical and Clinical Activities -by Byoung Chul Cho Byoung Chul Cho, M.D., Ph.D. and colleagues #ESMO24 doi.org/10.1158/2159-8… Yonsei University #D3Bio

Exciting #ESMO24 presentation by Byoung Chul Cho, M.D., Ph.D. Yonsei University on the ph1 activity of the KRAS G12C inhibitor D3S-001 (which locks KRAS G12C in its inactive GDP-bound form), the preclinical and initial clinical efficacy of which was published last week 👉🏻 aacrjournals.org/cancerdiscover…